Mexoimmu evaluates personalized immune characteristics through immune cell functional analysis, assisting healthcare professionals in developing customized assessment strategies and targeted clinical planning.
Beyond integrating immune cell percentages and culture circulating tumor cell (CTC) typing, Mexoimmu introduces immunopeptides to analyze cellular interactions between immune cells and CTCs under varying immunomodulatory conditions. This enables the screening of immunopeptides that most effectively boost immune cell function, providing valuable references for medical teams to tailor clinical treatment strategies. Furthermore, Mexoimmu establishes an immune cell-CTC co-culture model that mimics the in vivo microenvironment to evaluate the impact of different immune conditions on CTC viability. By providing objective data, Mexoimmu helps professionals master cellular functional profiles as a critical reference for personalized healthcare planning.
Immune Cell Percentage Analysis utilizes flow cytometry to analyze the proportions of key immune cell populations—including T cells, B cells, and Natural Killer (NK) cells—to assess the overall state of the immune system, serving as an essential baseline for immune function evaluation and health management.
CTC Subtype Profiling employs proprietary cell expansion technology to culture circulating tumor cells (CTCs) and circulating hybrid cells (CHCs) from blood samples. Flow cytometry is then used to analyze eight major cancer cell types, providing vital reference data for cancer risk assessment, disease monitoring, and treatment response tracking.
Immune Cell & CTC Co-Culture Analysis establishes an ex vivo functional assay model using autologous peripheral blood mononuclear cells (PBMCs) to co-culture immune cells with CTCs. By observing cellular interactions and viability dynamics between the two populations, this analysis yields crucial reference data to inform subsequent clinical interventions.
Immunopeptide Functional Screening evaluates functional efficacy by introducing six distinct immunopeptides to analyze their effects on immune cell activation, immune cell-CTC interactions, and CTC functional responses. This creates a personalized cellular functional profile to support tailored program evaluation and clinical planning.
Individuals with immune testing needs who wish to gain a more comprehensive understanding of the functional performance of their own immune cells
Individuals who need to conduct a comprehensive comparison of cellular functional changes and response differences under various immunomodulatory conditions
Individuals who wish to establish a personalized cell analysis database as a reference for future professional evaluations and program planning
Collect approximately 60 mL of human peripheral blood at a partner institution. The specimen will be delivered to the laboratory within 24 hours to initiate subsequent cell culture and testing analysis.
Utilize flow cytometry analysis technology to test the proportions of key immune cells, such as T cells, B cells, and NK cells, thereby evaluating individual immune status.
Employ proprietary culture technology to culture and expand immune cells and CTCs for subsequent immunopeptides testing. Concurrently, through immune cell and CTC co-culture, evaluate the cytotoxic effects of different immune cell types on CTCs.
In the immunopeptides testing, co-culture immune cells with CTCs in combination with 6 immunopeptide drugs to evaluate changes in CTC viability.
Utilize flow cytometry analysis technology to detect eight cancer-related CTC types and evaluate the potential quantity of CTCs in the body, providing references for early risk assessment and health management.
Integrate and comprehensively analyze all test results to issue an exclusive test report, serving as an important reference for developing personalized treatment plans.
Report Delivered in Approximately 14 Working Days
